The development of immunotherapeutic methods for the treatment of oncological diseases
have made it possible to improve the effectiveness of standard therapies. There was no …

The tumor microenvironment (TME) in ovarian cancer (OC) has much greater complexity
than previously understood. In response to aggressive pro-angiogenic stimulus, blood …

Dendritic cell (DC)-based vaccination for cancer treatment has seen considerable
development over recent decades. However, this field is currently in a state of flux toward …

Despite advances in surgery and chemotherapy, ovarian cancer remains one of the most
lethal malignancies. Hence, the implementation of novel treatment approaches is required to …

Cancer is a disease that induces many local and systemic changes in immunity. The difficult
nature of ovarian cancer stems from the lack of characteristic symptoms that contributes to a …

Cancer is the second leading cause of death worldwide and epidemiological projections
predict growing cancer mortality rates in the next decades. Cancer has a close relationship …

Simple Summary With an overall 5-year survival of only 20% for advanced-stage ovarian
cancer patients, enduring and effective therapies are a highly unmet clinical need. Current …

Dendritic cells (DCs) are antigen presenting cells that link innate and adaptive immunity.
DCs have been historically considered as the most effective and potent cell population to …

Ovarian cancer (OC) is an aggressive malignancy characterized by a complex
immunosuppressive tumor microenvironment (TME). Immune checkpoint inhibitors have …

Dendritic cells (DCs) are a heterogenous population of professional antigen presenting cells
whose main role is diminished in a variety of malignancies, including cancer, leading to …